Targeting the AAA ATPase p97 as an Approach to Treat Cancer through Disruption of Protein Homeostasis von Anderson, Daniel J., Le Moigne, Ronan, Djakovic, Stevan, Kumar, Brajesh, Rice, Julie, Wong, Steve, Wang, Jinhai, Yao, Bing, Valle, Eduardo, Kiss von Soly, Szerenke, Madriaga, Antonett, Soriano, Ferdie, Menon, Mary-Kamala, Wu, Zhi Yong, Kampmann, Martin, Chen, Yuwen, Weissman, Jonathan S., Aftab, Blake T., Yakes, F. Michael, Shawver, Laura, Zhou, Han-Jie, Wustrow, David, Rolfe, Mark

Volltext

Discovery of a First-in-Class, Potent, Selective, and Orally Bioavailable Inhibitor of the p97 AAA ATPase (CB-5083) von Zhou, Han-Jie, Wang, Jinhai, Yao, Bing, Wong, Steve, Djakovic, Stevan, Kumar, Brajesh, Rice, Julie, Valle, Eduardo, Soriano, Ferdie, Menon, Mary-Kamala, Madriaga, Antonett, Kiss von Soly, Szerenke, Kumar, Abhinav, Parlati, Francesco, Yakes, F. Michael, Shawver, Laura, Le Moigne, Ronan, Anderson, Daniel J, Rolfe, Mark, Wustrow, David

Volltext

Crystal structure of the proteasomal deubiquitylation module Rpn8-Rpn11 von Pathare, Ganesh Ramnath, Nagy, István, Śledź, Paweł, Anderson, Daniel J., Zhou, Han-Jie, Pardon, Els, Steyaert, Jan, Förster, Friedrich, Bracher, Andreas, Baumeister, Wolfgang

Volltext

The p97 Inhibitor CB-5083 Is a Unique Disrupter of Protein Homeostasis in Models of Multiple Myeloma von Le Moigne, Ronan, Aftab, Blake T, Djakovic, Stevan, Dhimolea, Eugen, Valle, Eduardo, Murnane, Megan, King, Emily M, Soriano, Ferdie, Menon, Mary-Kamala, Wu, Zhi Yong, Wong, Stephen T, Lee, Grace J, Yao, Bing, Wiita, Arun P, Lam, Christine, Rice, Julie, Wang, Jinhai, Chesi, Marta, Bergsagel, P Leif, Kraus, Marianne, Driessen, Christoph, Kiss von Soly, Szerenke, Yakes, F Michael, Wustrow, David, Shawver, Laura, Zhou, Han-Jie, Martin, 3rd, Thomas G, Wolf, Jeffrey L, Mitsiades, Constantine S, Anderson, Daniel J, Rolfe, Mark

Volltext

Design and Synthesis of an Orally Bioavailable and Selective Peptide Epoxyketone Proteasome Inhibitor (PR-047) von Zhou, Han-Jie, Aujay, Monette A, Bennett, Mark K, Dajee, Maya, Demo, Susan D, Fang, Ying, Ho, Mark N, Jiang, Jing, Kirk, Christopher J, Laidig, Guy J, Lewis, Evan R, Lu, Yan, Muchamuel, Tony, Parlati, Francesco, Ring, Eileen, Shenk, Kevin D, Shields, Jamie, Shwonek, Peter J, Stanton, Timothy, Sun, Congcong M, Sylvain, Catherine, Woo, Tina M, Yang, Jinfu

Volltext

CB-6644 Is a Selective Inhibitor of the RUVBL1/2 Complex with Anticancer Activity von Assimon, Victoria A, Tang, Yangzhong, Vargas, Jesse D, Lee, Grace J, Wu, Zhi Yong, Lou, Kenny, Yao, Bing, Menon, Mary-Kamala, Pios, Ariel, Perez, Kristy C, Madriaga, Antonett, Buchowiecki, Peter K, Rolfe, Mark, Shawver, Laura, Jiao, Xianyun, Le Moigne, Ronan, Zhou, Han-Jie, Anderson, Daniel J

Volltext

Lessons learned from the metastatic castration-resistant prostate cancer phase I trial of EPI-506, a first-generation androgen receptor N-terminal domain inhibitor von Le Moigne, Ronan, Zhou, Han-Jie, Obst, Jon K., Banuelos, C. Adriana, Jian, Kunzhong, Williams, David, Virsik, Peter, Andersen, Raymond J, Sadar, Marianne, Perabo, Frank, Chi, Kim N.

Volltext

Ferroelectric Ceramic Materials Enable High-Performance Organic-Inorganic Composite Electrolytes in Solid-State Lithium Metal Batteries von Ma, Jing-Yuan, Huang, Yu-Li, Zhou, Han-Jie, Wang, Yuan-Yuan, Li, Jian-Gang, Yu, Xi-Qian, Li, Hong, Li, Yan

Volltext

Discovery of the First Potent and Selective Inhibitor of Centromere-Associated Protein E: GSK923295 von Qian, Xiangping, McDonald, Andrew, Zhou, Han-Jie, Adams, Nicholas D, Parrish, Cynthia A, Duffy, Kevin J, Fitch, Duke M, Tedesco, Rosanna, Ashcraft, Luke W, Yao, Bing, Jiang, Hong, Huang, Jennifer K, Marin, Melchor V, Aroyan, Carrie E, Wang, Jianchao, Ahmed, Seyed, Burgess, Joelle L, Chaudhari, Amita M, Donatelli, Carla A, Darcy, Michael G, Ridgers, Lance H, Newlander, Ken A, Schmidt, Stanley J, Chai, Deping, Colón, Mariela, Zimmerman, Michael N, Lad, Latesh, Sakowicz, Roman, Schauer, Stephen, Belmont, Lisa, Baliga, Ramesh, Pierce, Daniel W, Finer, Jeffrey T, Wang, Zhengping, Morgan, Bradley P, Morgans, David J, Auger, Kurt R, Sung, Chiu-Mei, Carson, Jeff D, Luo, Lusong, Hugger, Erin D, Copeland, Robert A, Sutton, David, Elliott, John D, Jackson, Jeffrey R, Wood, Kenneth W, Dhanak, Dashyant, Bergnes, Gustave, Knight, Steven D

Volltext

Preclinical and clinical pharmacology of EPI-7386, an androgen receptor N-terminal domain inhibitor for castration-resistant prostate cancer von Le Moigne, Ronan, Pearson, Paul, Lauriault, Veronique, Hong, Nan Hyung, Virsik, Peter, Zhou, Han-Jie, Cesano, Alessandra

Volltext

Discovery of an Inhibitor of the Proteasome Subunit Rpn11 von Perez, Christian, Li, Jing, Parlati, Francesco, Rouffet, Matthieu, Ma, Yuyong, Mackinnon, Andrew L, Chou, Tsui-Fen, Deshaies, Raymond J, Cohen, Seth M

Volltext

Abstract 1209: Comprehensive in vitro characterization of the mechanism of action of EPI-7386, an androgen receptor N-terminal domain inhibitor von Hong, Nan Hyung, Sun, Shihua, Virsik, Peter, Cesano, Alessandra, Mostaghel, Elahe A., Plymate, Stephen R., Zhou, Han-Jie, Moigne, Ronan Le

Volltext

Abstract P192: Comprehensive preclinical characterization of the mechanism of action of EPI-7386, an androgen receptor N-terminal domain inhibitor von Hong, Nan Hyung, Sun, Shihua, Virsik, Peter, Cesano, Alessandra, Mostaghel, Elahe A., Plymate, Stephen R., Biannic, Berenger, Zhou, Han-Jie, Le Moigne, Ronan

Volltext

IND candidate EPI-7386 as an N-terminal domain androgen receptor inhibitor in development for the treatment of prostate cancer von Le Moigne, Ronan, Banuelos, C. Adriana, Mawji, Nasrin R., Tam, Teresa, Wang, Jun, Jian, Kunzhong, Andersen, Raymond J., Cesano, Alessandra, Sadar, Marianne, Zhou, Han-Jie, Virsik, Peter

Volltext

Abstract 1292: A new generation of N-terminal domain androgen receptor inhibitors, with improved pharmaceutical properties, in castration-resistant prostate cancer models von Moigne, Ronan Le, Mawji, Nasrin R., Banuelos, C. Adriana, Wang, Jun, Jian, Kunzhong, Andersen, Raymond J., Sadar, Marianne D., Zhou, Han-Jie, Virsik, Peter

Volltext

Abstract B117: Treatment of castrated resistant prostate cancer with EPI-7386, a second generation N-terminal domain androgen receptor inhibitor von Moigne, Ronan Le, Banuelos, C. Adriana, Mawji, Nasrin R, Tam, Teresa, Wang, Jun, Jian, Kunzhong, Andersen, Raymond J, Cesano, Alessandra, Sadar, Marianne D, Zhou, Han-Jie, Virsik, Peter

Volltext

Abstract 1953: Pre-clinical development of the second-generation N-terminal domain androgen receptor inhibitor, EPI-7386, for the treatment of prostate cancer von Hong, Nan Hyung, Moigne, Ronan Le, Banuelos, C. Adriana, Mawji, Nasrin R., Tam, Teresa, Wang, Jun, Andersen, Raymond J., Cesano, Alessandra, Sadar, Marianne D., Zhou, Han-Jie, Virsik, Peter

Volltext

Next generation N-terminal domain androgen receptor inhibitors with improved potency and metabolic stability in castration-resistant prostate cancer models von Le Moigne, Ronan, Zhou, Han-Jie, Mawji, Nasrin R, Banuelos, C. Adriana, Wang, Jun, Jian, Kunzhong, Virsik, Peter, Andersen, Raymond J, Sadar, Marianne

Volltext

Abstract 429: Androgen receptor (AR) N-terminal domain degraders can degrade AR full length and AR splice variants in CRPC preclinical models von Hong, Nan Hyung, Biannic, Berenger, Virsik, Peter, Zhou, Han-Jie, Moigne, Ronan Le

Volltext

Abstract 2: Discovery of BAY 2402234 by phenotypic screening: A human Dihydroorotate Dehydrogenase (DHODH) inhibitor in clinical trials for the treatment of myeloid malignancies von Gradl, Stefan N., Mueller, Thomas, Ferrara, Steven, Sheikh, Sherif El, Janzer, Andreas, Zhou, Han-Jie, Friberg, Anders, Guenther, Judith, Schaefer, Martina, Stellfeld, Timo, Eis, Knut, Kroeber, Michael, Nguyen, Duy, Merz, Claudia, Niehues, Michael, Stoeckigt, Detlef, Christian, Sven, Zimmermann, Katja, Lejeune, Pascal, Bruening, Michael, Meyer, Hanna, Puetter, Vera, Scadden, David T., Sykes, David B., Seidel, Henrik, Eheim, Ashley, Michels, Martin, Haegebarth, Andrea, Bauser, Marcus

Volltext